tradingkey.logo

Nanovibronix Inc

NAOV
4.020USD
0.0000.00%
Close 02/06, 16:00ETQuotes delayed by 15 min
4.06MMarket Cap
LossP/E TTM

Nanovibronix Inc

4.020
0.0000.00%

More Details of Nanovibronix Inc Company

NanoVibronix, Inc. is a medical device company focused on developing medical devices utilizing its patented low intensity surface acoustic wave (SAW) technology. The technology allows for the creation of low-frequency ultrasound waves that can be utilized for a variety of medical applications, including for disruption of biofilms and bacterial colonization, as well as for pain relief. The Company's primary products include PainShield and UroShield, which are portable devices suitable for administration at home or in any care setting. PainShield is a patch-based therapeutic ultrasound technology to treat pain, muscle spasm and joint contractures by delivering a localized ultrasound effect to treat pain and induce soft tissue healing in a targeted area. UroShield is an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy and decrease pain and discomfort associated with urinary catheter use.

Nanovibronix Inc Info

Ticker SymbolNAOV
Company nameNanovibronix Inc
IPO dateApr 24, 2015
CEOBesser (Doron)
Number of employees15
Security typeOrdinary Share
Fiscal year-endApr 24
Address969 Pruitt Piace
CityTYLER
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code75703
Phone19142333004
Websitehttps://nanovibronix.com/
Ticker SymbolNAOV
IPO dateApr 24, 2015
CEOBesser (Doron)

Company Executives of Nanovibronix Inc

Name
Name/Position
Position
Shareholding
Change
Mr. Stephen Russell (Steve) Brown
Mr. Stephen Russell (Steve) Brown
Chief Financial Officer
Chief Financial Officer
2.00
--
Dr. Harold Jacob, M.D.
Dr. Harold Jacob, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Doron Besser, M.D.
Dr. Doron Besser, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Prof. Zeev Rotstein
Prof. Zeev Rotstein
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Stephen Russell (Steve) Brown
Mr. Stephen Russell (Steve) Brown
Chief Financial Officer
Chief Financial Officer
2.00
--
Dr. Harold Jacob, M.D.
Dr. Harold Jacob, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Doron Besser, M.D.
Dr. Doron Besser, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Prof. Zeev Rotstein
Prof. Zeev Rotstein
Independent Director
Independent Director
--
--

Revenue Breakdown

Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
462.00K
93.52%
New Zealand
20.00K
4.05%
Europe
8.00K
1.62%
Other
4.00K
0.81%
By Business
By Region
Relevant data have not been disclosed by the company yet.

Shareholding Stats

Updated: Fri, Jan 2
Updated: Fri, Jan 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Alpha Capital Aktiengesellschaft
0.76%
Geode Capital Management, L.L.C.
0.49%
Armistice Capital LLC
0.37%
Morgan Stanley Smith Barney LLC
0.09%
Tower Research Capital LLC
0.06%
Other
98.23%
Shareholders
Shareholders
Proportion
Alpha Capital Aktiengesellschaft
0.76%
Geode Capital Management, L.L.C.
0.49%
Armistice Capital LLC
0.37%
Morgan Stanley Smith Barney LLC
0.09%
Tower Research Capital LLC
0.06%
Other
98.23%
Shareholder Types
Shareholders
Proportion
Holding Company
0.76%
Investment Advisor/Hedge Fund
0.49%
Hedge Fund
0.42%
Investment Advisor
0.11%
Other
98.21%

Institutional Shareholding

Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
17
11.24K
1.03%
+4.25K
2025Q3
17
5.95K
0.68%
+2.34K
2025Q2
26
142.96K
5.53%
+80.02K
2025Q1
26
100.49K
7.64%
+70.73K
2024Q4
29
390.46K
7.75%
-206.57K
2024Q3
31
421.26K
15.22%
+83.76K
2024Q2
31
243.60K
8.84%
-214.51K
2024Q1
34
373.91K
18.23%
+170.33K
2023Q4
38
117.62K
5.71%
-262.96K
2023Q3
41
131.29K
7.90%
-1.54K
View more

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
Alpha Capital Aktiengesellschaft
8.25K
0.76%
+4.93K
+148.55%
May 16, 2025
Geode Capital Management, L.L.C.
5.14K
0.47%
--
--
Nov 30, 2025
Armistice Capital LLC
3.99K
0.37%
+3.99K
--
Mar 31, 2025
Morgan Stanley Smith Barney LLC
1.00K
0.09%
+1.00K
--
Sep 30, 2025
Tower Research Capital LLC
627.00
0.06%
+401.00
+177.43%
Sep 30, 2025
The Vanguard Group, Inc.
189.00
0.02%
--
--
Nov 30, 2025
UBS Financial Services, Inc.
35.00
0%
-1.33K
-97.45%
Sep 30, 2025
Fashek (Christopher M)
34.00
0%
--
--
Oct 27, 2025
SBI Securities Co., Ltd.
15.00
0%
+15.00
--
Sep 30, 2025
BofA Global Research (US)
6.00
0%
+5.00
+500.00%
Sep 30, 2025
View more

Related ETFs

Name
Proportion
No Data

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Splits

Date
Ex-dividend Date
Type
Ratio
Aug 08, 2025
Merger
10→1
Feb 25, 2025
Merger
11→1
Feb 25, 2025
Merger
11→1
Feb 25, 2025
Merger
11→1
Feb 08, 2023
Merger
20→1
Feb 08, 2023
Merger
20→1
Date
Ex-dividend Date
Type
Ratio
Aug 08, 2025
Merger
10→1
Feb 25, 2025
Merger
11→1
Feb 25, 2025
Merger
11→1
Feb 25, 2025
Merger
11→1
Feb 08, 2023
Merger
20→1
Feb 08, 2023
Merger
20→1
Feb 08, 2023
Merger
20→1
Feb 08, 2023
Merger
20→1
KeyAI